Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × veliparib × Gynecologic × Clear all

Phase

Phase 1 15 Phase 2 4 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Breast 2 Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 130 Carboplatin 95 Cisplatin 80 Bevacizumab 35 Topotecan 32 Gemcitabine 31 Radiotherapy 28 liposomal doxorubicin 27 Doxorubicin 27 Brachytherapy 24 Taxes 23 olaparib 18 Drug Therapy 18 pembrolizumab 16 Chemotherapy, Adjuvant 16 human papillomavirus vaccine, L1 type 16, 18 14 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 13 Hyperthermic Intraperitoneal Chemotherapy 12 Docetaxel 12 Platinum 10 Neoadjuvant Therapy 10 niraparib 9 Radiation 9 1,2-diaminocyclohexaneplatinum II citrate 9 Vaccines, Synthetic 8 Surgical Procedures, Operative 7 Specimen Handling 7 Papillomavirus Vaccines 7 Immunoglobulin G 7 Filgrastim 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02470585 2024-10-26

VELIA

AbbVie

Phase 3 Terminated

1,140 enrolled 29 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡